3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 4
1
Phase 2/3
1
Phase 2
1
Phase 1
1
Status
Completed
4
Recruiting
3
Terminated
2
Withdrawn
1
Unknown
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
1
Genitourinary
1
Endocrine
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors in Lung
1
Interventions
Cisplatin
62
Carboplatin
52
Paclitaxel
48
Radiotherapy
47
Docetaxel
41
Gemcitabine
38
Cyclophosphamide
36
Rituximab
33
Capecitabine
28
Fluorouracil
27
Dexamethasone
27
Doxorubicin
26
Prednisone
21
Bevacizumab
20
Pemetrexed
19
Oxaliplatin
18
Leucovorin
18
pembrolizumab
17
Vincristine
17
Etoposide
17
Cytarabine
15
Drug Therapy
14
Irinotecan
13
Imatinib Mesylate
13
Filgrastim
13
Zoledronic Acid
12
Radiosurgery
12
Erlotinib Hydrochloride
12
Trastuzumab
11
Goserelin
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Terminated
×
lanreotide
×
Clear all
NCT02683941
2022-07-06
SPINET
Ipsen
Phase 3
Terminated
77 enrolled
20 charts
NCT01313273
2019-11-22
POSEIDON
Ipsen
Phase 3
Terminated
3 enrolled
4 charts